NCT06111326View on ClinicalTrials.gov

BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

August 31, 2024

Study Completion Date

May 31, 2026

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

BC3402 injection

Intravenous infusion, once every 2 weeks, 4 weeks/cycle.

DRUG

Durvalumab injection

Intravenous infusion, once every 4 weeks, 4 weeks/cycle.

Trial Locations (1)

Unknown

Zhongshan Hospital, Fudan University, Shanghai

Sponsors
All Listed Sponsors
lead

Biocity Biopharmaceutics Co., Ltd.

INDUSTRY